Alignment Healthcare (NASDAQ:ALHC) Stock Price Target Lowered at JPMorgan Chase & Co.

Alignment Healthcare (NASDAQ:ALHC) had its price objective decreased by research analysts at JPMorgan Chase & Co. from $22.00 to $10.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 32.45% from the company’s previous close.

ALHC has been the topic of several other research reports. Raymond James Financial cut shares of Alignment Healthcare from a “strong-buy” rating to an “outperform” rating and reduced their price target for the stock from $22.00 to $19.00 in a research report on Monday, August 3rd. KeyCorp cut their price objective on Alignment Healthcare from $28.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday. William Blair downgraded Alignment Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday. Wall Street Zen lowered Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Barclays lowered their price target on Alignment Healthcare from $16.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.18.

Alignment Healthcare Stock Down 13.3%

Shares of NASDAQ:ALHC traded down $1.16 during midday trading on Friday, reaching $7.55. The company had a trading volume of 21,301,121 shares, compared to its average volume of 5,567,272. The stock has a market capitalization of $1.57 billion, a P/E ratio of 40.03 and a beta of 1.14. The stock’s fifty day moving average price is $11.64 and its 200-day moving average price is $16.70. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.70. Alignment Healthcare has a one year low of $6.01 and a one year high of $25.12.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. The firm had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.31 billion. Alignment Healthcare had a net margin of 0.89% and a return on equity of 20.02%. The firm’s revenue was up 31.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.07 EPS. Equities research analysts expect that Alignment Healthcare will post 0.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Joseph Konowiecki sold 23,511 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $8.61, for a total transaction of $202,429.71. Following the sale, the executive vice president directly owned 1,080,305 shares in the company, valued at approximately $9,301,426.05. This represents a 2.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hyong Kim sold 32,479 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $8.30, for a total value of $269,575.70. Following the transaction, the insider owned 299,271 shares of the company’s stock, valued at $2,483,949.30. This represents a 9.79% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,061,967 shares of company stock valued at $13,642,490 over the last three months. 5.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alignment Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of ALHC. PNC Financial Services Group Inc. grew its position in Alignment Healthcare by 9.2% in the first quarter. PNC Financial Services Group Inc. now owns 11,445 shares of the company’s stock worth $202,000 after buying an additional 962 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Alignment Healthcare by 46.6% during the 2nd quarter. GAMMA Investing LLC now owns 3,368 shares of the company’s stock worth $80,000 after acquiring an additional 1,070 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Alignment Healthcare by 463.3% in the 2nd quarter. Versant Capital Management Inc now owns 1,380 shares of the company’s stock worth $33,000 after acquiring an additional 1,135 shares during the last quarter. Nykredit A S acquired a new position in shares of Alignment Healthcare in the 2nd quarter worth $36,000. Finally, Strs Ohio raised its position in shares of Alignment Healthcare by 10.2% during the first quarter. Strs Ohio now owns 24,900 shares of the company’s stock worth $439,000 after purchasing an additional 2,300 shares during the period. Institutional investors and hedge funds own 86.19% of the company’s stock.

Trending Headlines about Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Six of Alignment Healthcare’s seven eligible Medicare Advantage contracts earned 4 Stars or higher, including three plans that received 4.5 Stars. The contracts cover markets in Arizona, California, Nevada, North Carolina and Texas, supporting the company’s quality-care positioning. Alignment Healthcare 2027 Star Ratings
• Positive Sentiment: KeyCorp lowered its price target from $28 to $12 but maintained an “overweight” rating, implying substantial potential upside from recent trading levels and signaling that the analyst views the selloff as excessive.
• Neutral Sentiment: Alignment disputed the 3.5-Star rating for its California H3815 HMO contract, arguing that it conflicts with the plan’s clinical outcomes, quality measures and member-experience results. The company intends to pursue administrative remedies and possible litigation, although the outcome and timing are uncertain. Alignment Healthcare Stock and 2027 Star Ratings
• Negative Sentiment: The California H3815 HMO contract received only 3.5 Stars. Investors appear concerned that the lower rating could reduce the plan’s competitive appeal and affect future Medicare Advantage economics, helping drive the sharp decline in ALHC. Alignment Healthcare Medicare Plan Downgrade
• Negative Sentiment: William Blair downgraded Alignment Healthcare to “Market Perform,” adding to pressure on the stock. The company also faces a reduced valuation benchmark after KeyCorp’s target cut, even though KeyCorp retained its bullish rating. William Blair Downgrade
• Negative Sentiment: Recent insider selling—including a 32,479-share sale by Chief Medical Officer Hyong Kim—adds to investor caution, though the transaction was reported as being used to cover tax withholding on vested equity awards.

About Alignment Healthcare

Alignment Healthcare, Inc is a technology-enabled Medicare Advantage company focused on providing health coverage and care services for older adults. The company offers Medicare Advantage plans that combine medical benefits with care coordination, wellness support, and other services designed to help members manage their health.

Alignment operates through an integrated healthcare model that uses its proprietary technology platform to support physicians, care teams, and members. Its services include personalized care management, clinical coordination, virtual and in-home support, and member assistance through its concierge-style approach.